DRI Healthcare Exercises Put Option on EKTERLY® for $178M
Event summary
- DRI Healthcare exercised its put option on EKTERLY® (sebetralstat) for a net repurchase price of approximately $178 million.
- The Put Option was exercised following Chiesi Group's acquisition of KalVista Pharmaceuticals, Inc. on June 11, 2026.
- DRI Healthcare expects to receive the payment no later than mid-August 2026.
- This marks DRI Healthcare's first pre-approval transaction.
The big picture
DRI Healthcare's exercise of the put option on EKTERLY® underscores its strategy of monetizing royalty participation rights in biopharmaceutical assets. The $178 million proceeds reflect the quality of DRI Healthcare's underwriting and its ability to crystallize attractive returns for unitholders. This transaction comes at a time when the biopharmaceutical industry is witnessing increased consolidation, with major players like Chiesi Group acquiring innovative assets to bolster their portfolios.
What we're watching
- Proceeds Redeployment
- How DRI Healthcare will redeploy the $178 million proceeds into the biopharmaceutical industry to generate long-term value for unitholders.
- Market Impact
- The potential impact of this transaction on DRI Healthcare's unit prices and investor confidence.
- Future Transactions
- Whether this successful pre-approval transaction will set a precedent for future deals involving pre-approval assets.
Related topics